July 2026 Research Update

This month added a clearer message that Niemann-Pick disease type C (NPC) can be missed when standard genetic testing or look-alike diagnoses do not fully fit, and that looking at how the gene is actually used (RNA testing) can sometimes uncover the cause. One report combined a new patient with a literature review showing that "hidden" intronic NPC1 changes can disrupt splicing (how a gene is pieced together) even when they are not near the usual splice sites. Another report showed how NPC can mimic Wilson disease on some lab tests and scoring systems, leading to years of incorrect labeling until NPC1 gene results clarified the diagnosis. [1] [2]

In the RNA-focused report, conventional genetic testing was inconclusive, but RNA sequencing done on skin cells found a deep intronic NPC1 variant that caused abnormal splicing, supporting NPC as the explanation for the person’s neurologic symptoms. The accompanying review identified 12 previously reported patients with intronic splice-altering variants outside the usual splice-site regions, with many having juvenile- or adult-onset disease and varied biomarker patterns. Together, these findings make it more concrete that some genetically "unsolved" NPC cases may be solvable by testing that looks beyond typical DNA variant locations and checks the RNA effect directly. [1]

In the Wilson disease mimic report, a man had splenomegaly and low ceruloplasmin and met a Wilson disease score threshold, yet important Wilson disease signs were missing and the course was slow. Genetic testing later found two pathogenic NPC1 variants, reframing the earlier abnormal copper-related labs as potentially misleading in this context. This case adds a practical reminder that when a diagnosis based on indirect markers does not fully match the overall picture, definitive genetic results can be the deciding factor. [2]

For patients and caregivers, these studies mainly matter at the diagnosis stage, especially when earlier testing did not give a clear answer or when another condition was diagnosed but the symptoms do not line up well. The work on RNA sequencing suggests a concrete path that research and specialist labs sometimes use to find deep intronic NPC1 changes that standard tests may miss, but it is not yet described here as a routine step for every person with possible NPC. The Wilson disease mimic case highlights that some blood tests can point toward other conditions, so a confirmed NPC1 finding can be important for settling uncertainty and avoiding long periods of pursuing the wrong explanation. [1] [2]

This month did not add new large clinical trial results, but it did add real-world, person-by-person descriptions of how symptoms changed after starting treatments used or studied in NPC. Across the reports, miglustat (a disease-specific medicine used in NPC) was linked with stabilization or improvement in certain symptoms, while other symptoms continued to progress. One child’s report also described partial improvements during participation in a phase III trial of N-acetyl-L-leucine, alongside the appearance of cataplexy during follow-up. [1] [3] [2]

In a genetically clarified case that required RNA sequencing to find the underlying NPC1 problem, starting miglustat was followed by clinical stabilization. In an adult who had been treated for years as if he had Wilson disease, starting miglustat was followed by improved swallowing after 3 months, while gait instability persisted. These experiences add detail to a common reality in NPC care: changes may be symptom-specific, and the same treatment may not affect every problem in the same way. [1] [2]

In a 6-year-old boy with early liver involvement and later progressive neurologic symptoms, miglustat was followed by early improvement in gait, eye movement function, and swallowing, but cognitive and behavioral decline continued over time. During later follow-up within a phase III trial of N-acetyl-L-leucine, the report described partial improvement in communication, behavior, and swallowing, with supervised gait improvement, and noted the emergence of cataplexy. Because this is a single-person description within a trial setting, it cannot show how often these changes happen, but it does clarify which daily-life functions were observed to shift in this child. [3]

For families, these case reports mainly add expectation-setting about the range of possible symptom changes that can be observed over time in individual people, rather than proving how well a treatment works on average. They suggest that swallowing, gait, eye movement problems, communication, and behavior can change in different directions or at different speeds, even within the same person taking miglustat or while enrolled in research involving N-acetyl-L-leucine. What remains uncertain is how general these experiences are, since case reports do not include comparison groups and may reflect unique circumstances. These findings may be most useful for understanding what researchers and clinicians are watching in NPC studies and follow-up, rather than changing anything immediately on their own. [1] [3] [2]

This month’s laboratory research focused less on new patient outcomes and more on explaining what may be going wrong inside NPC cells, and which pathways might be adjustable with drugs. One cell study reported that N-acetyl-L-leucine pushed a key lysosome-control protein (TFEB) in opposite directions depending on whether cells were normal or NPC-like, bringing over-activation in NPC models closer to typical levels. A broader multi-model study reported that fingolimod improved several disease-related signals in NPC models, including lysosomal function and inflammation, and extended lifespan in aged male mice and in worms, while not reducing the underlying DNA damage that was measured. [4] [5]

In the cell study, N-acetyl-L-leucine changed how much TFEB was found in the cell nucleus, which is important because TFEB can turn on many genes involved in lysosome function. The researchers reported a "normalizing" pattern: TFEB activity increased in normal cells but decreased toward typical levels in NPC1-deficient or NPC-like cells where TFEB was already over-activated, along with related changes in lysosomal markers. This helps clarify a possible reason the same compound could have different effects depending on the cell’s starting state, although cell models cannot predict symptom changes in people. [4]

In the multi-model study, NPC1 deficiency was described as triggering a linked set of problems spanning lysosomes, immune signaling, and aging-like changes, which the authors connected to neurodegeneration in the mouse model. Fingolimod partially reversed several measured problems in NPC models, including lysosomal cholesterol handling, inflammatory signaling, and neurodegenerative and neuroinflammatory readouts, and it shifted broad gene activity toward a healthier pattern. The study also reported sex-specific effects and noted that fingolimod did not reduce the measured DNA damage, which narrows what this approach might be expected to change if it ever reaches human testing. [5]

For patients and caregivers, these findings are early research that may matter later, because they are not reports of treatment benefit in people with NPC. They do help make the biology more understandable by pointing to specific cell control systems (like TFEB and lysosome function) and to immune-related pathways that may be involved alongside cholesterol buildup. They also help clarify that a drug can improve some measured disease features in models without fixing every underlying problem (such as DNA damage in this report), which is important for setting realistic research goals. What remains uncertain is whether the same pathway changes can be safely achieved in people and whether they would translate into meaningful symptom changes. [4] [5]